MeiraGTx Holdings (FRA:328) Moat Score: 4/10 (As of Jul. 03, 2026)


FRA:328 MeiraGTx Holdings PLC FRA:328
55 GF Score
Price €11.10
GF Value €19.03
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MeiraGTx Holdings Moat Score?

MeiraGTx Holdings FRA:328 -5.13% 55 Moat Score is 4 as of Jul. 03, 2026. GuruFocus rates FRA:328 with a GF Score™ of 55/100 and a GF Value™ of €19.03 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,399 Biotechnology companies, MeiraGTx Holdings ranks better than 88.78% on this metric.

MeiraGTx Holdings has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

MeiraGTx Holdings has Narrow Moat: MeiraGTx has valuable intellectual property in gene therapy, providing some protection. However, the market is competitive with limited customer switching costs and brand strength, resulting in a modest moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes MeiraGTx Holdings might have Narrow Moat - Discernible but modest moat.

MeiraGTx Holdings  (FRA:328) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

MeiraGTx Holdings Moat Score Related Terms

FRA:328 vs XNCR, WVE, CGEM: Moat Score Comparison

For the Biotechnology subindustry, MeiraGTx Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MeiraGTx Holdings Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where MeiraGTx Holdings's Moat Score falls into.


FRA:328
55GF Score
MeiraGTx Holdings PLC FRA:328
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
MeiraGTx Holdings (FRA:328) has a Moat Score of 4 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, MeiraGTx Holdings ranks #157 out of 1399 companies in the Biotechnology industry, placing it in the top 11.2%.
Is MeiraGTx Holdings' Moat Score too high?
MeiraGTx Holdings' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. MeiraGTx Holdings' value of 4 is 100% above this industry median. Based on the distribution chart, MeiraGTx Holdings ranks #157 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MeiraGTx Holdings has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' Moat Score compare to XNCR and WVE?
According to the Biotechnology industry distribution chart, MeiraGTx Holdings ranks #157 out of 1399 companies for Moat Score. This places MeiraGTx Holdings in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. MeiraGTx Holdings' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MeiraGTx Holdings's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MeiraGTx Holdings's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (FRA:328) is currently considered Possible Value Trap. The stock's GF Value™ is €19.03, compared to a current price of €11.10 — trading 41.7% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. MeiraGTx Holdings' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For MeiraGTx Holdings (FRA:328), the current Moat Score is 4 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MeiraGTx Holdings (FRA:328) Overvalued in 2026?

Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued. The current stock price of €11.10 is trading 41.7% below its estimated GF Value™ of €19.03. GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.

Key valuation signals for FRA:328:

  • Moat Score: 4
  • GF Value™: €19.03 vs. price of €11.10 (41.7% below fair value)
  • GF Score™: 55/100 with 5 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1399)

No single metric tells the full story. See the FRA:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MeiraGTx Holdings Business Description

Other Exchanges MGTX:USA328:Germany
Address 655 Third Avenue, Suite 1115, New York, NY, USA, 10017
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
55GF Score

Get the complete analysis for FRA:328

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.10
Price
€19.03
GF Value